CATALYSTReuters • 2h ago
Indian shares rise on Iran war talks, Reliance earnings beat - ReutersIndian shares rise on Iran war talks, Reliance earnings beat Reuters
Why NEUP Stock dropped -8.93% Today — RQD Quant Desk Flash
$3.06 -8.93% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $3.00
Neuphoria Therapeutics Inc. (NEUP) carries a Roarable Rating of E (Strong Sell) with 32/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE E • RED ALERT
Cap $16.6M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on NEUP Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is NEUP stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-01, Neuphoria Therapeutics Inc. (NASDAQ: NEUP) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $3.06 (-8.93% 1D, market cap $16.6M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, NEUP ranks #899 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does NEUP compare to MRKR and RADX in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), NEUP carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -11.8%. By comparison, MRKR (Marker Therapeutics Inc.) holds a D grade (48/100 RQD, P/E N/A, ROIC -35.0%, cap $16.8M) and RADX (Radiopharm Theranostics Limited) posts a C- grade (61/100 RQD, P/E N/A, ROIC —, cap $16.1M). Among the 5-stock peer group, NEUP leads on earnings multiple (N/A) while NEUP leads on capital efficiency (-11.8% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for NEUP?
▼
Per NEUP's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-06-30, CIK 0001191070), Neuphoria Therapeutics Inc. generated $15.6M in revenue, -$369.6K in net income, and $77.2K in free cash flow against $36.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $3.00 (-1.80%)🧬 Dilution Drag (+1.92% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0.5% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (32/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.2% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • E
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk D-
Each axis scored 0–20
12M PRICE TARGET CONE-11.8% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for NEUP)Realized 20D OHLCV Swing Band: ±7.7%
Deterministic 5-Pillar Attribution (32/100 Composite)
🔍 WHY NEUP SCORES 32/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Cash Engine Quality+8/20 pts (25% of score)
SEC XBRL FY 2025 (10-K): 0.5% FCF Margin ($77.2K FCF) & 52% Gross Margin
▲ #2 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (25% of score)
Altman Z-Score 0.20 (DISTRESS RISK (<1.8)) • Piotroski F-Score 5/9
▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)
Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade D$3.36-1.8% Next Q
40
Q2 (-2Q)Grade E$3.30+4.2% Next Q
37
Q3 (-1Q)Grade E$3.44-11% Next Q
35
CurrentGrade E$3.06-9.2% Hist 90D α
32
Trajectory: D (40) → E (32)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a NEUP Turnaround Squeeze
While NEUP currently carries a cautious 32/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.57) and Max Pain ($3.21) forces dealer call-delta covering toward $5.81.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.92% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $NEUP• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “NEUP Beats Next Quarter EPS Consensus (Dec 28, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why NEUP Stock dropped -8.93% Today — RQD Quant Desk Flash
Neuphoria Therapeutics Inc. (NEUP) dropped -8.93% to $3.06, trading at 2% of its 52-week range ($3.03 – $5.53). Stretched risk/reward at current multiples (-12% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 2% of its 52-week range ($3.03 – $5.53) with RSI-14 at 25.4 (OVERSOLD (<32)).
- ▸Volatility Profile: Historical 20-day realized swing band of ±7.7% around $3.06 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 52% gross margin and $77229 annual free cash flow.
Live NEUP Headlines & Catalysts
MARKET WIREReuters • 6h ago
Russia's FSB says minor detained over park attack threat after US tip-off - ReutersRussia's FSB says minor detained over park attack threat after US tip-off Reuters
MARKET WIREReuters • 6h ago
Oil slips more than 1% as talks continue on ending Iran war - ReutersOil slips more than 1% as talks continue on ending Iran war Reuters
MARKET WIREReuters • 7h ago
Nine people dead in Learjet crash in south Florida, officials say - ReutersNine people dead in Learjet crash in south Florida, officials say Reuters
MARKET WIREReuters • 9h ago
Iran's IRGC Navy says two tankers 'exploded' after hitting mines in Hormuz - ReutersIran's IRGC Navy says two tankers 'exploded' after hitting mines in Hormuz Reuters
MARKET WIRECNBC • 11h ago
Here are 3 big things we're watching in the stock market in the week aheadThe market could use a few victories in the days ahead, which will be filled with more earnings, an election, and jobs data.
MARKET WIRECNBC • 11h ago
Democratic Rep. Stevens endorses Rogers over El-Sayed in Michigan Senate electionHaley Stevens had lost the Democratic nomination for Senate in Michigan to Abdul El-Sayed earlier this year.
RISK WATCHReuters • 12h ago
Israeli strikes kill eight people in Gaza - medics say - ReutersIsraeli strikes kill eight people in Gaza - medics say Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring NEUP)
- ✓Walkthrough of NEUP's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
NEUP // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -41.94%🛡️ HOLDING TREND SUPPORT
2026-10-30O $3.10H $3.11L $3.04C $3.06VOL 70.2K
RES: $3.51SUP: $3.06SMA50: $3.57SMA200: $4.16
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
NEUP Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on NEUP today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for NEUP. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for NEUP today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (NEUP)
Health Care Rank #899 of 1016
⚔️ MRKR vs NEUP Full Matrix →
1. Head-to-Head Health Care Peer Comparison (NEUP vs. MRKR, RADX, JAGX, AEON)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Neuphoria Therapeutics Inc. (NEUP) ranks #899 by composite RQD confidence (32/100, grade E) and #849 by equity capitalization ($16.6M). Within this direct 5-issuer industry benchmark cohort, NEUP leads on earnings valuation at N/A trailing P/E, while NEUP leads on capital efficiency and profitability with -11.8% ROIC and — gross margin. RADX currently holds the highest overall quantitative score in the immediate peer group at 61/100 (C-) compared with NEUP at 32/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| NEUP
ACTIVE
Neuphoria Therapeutics Inc. | E | 32/100 | — | — | -11.8% | -8.93% | $16.6M | Benchmark Subject |
| MRKR Marker Therapeutics Inc. | D | 48/100 | — | — | -35.0% | +1.00% | $16.8M | /mrkr-vs-neup → |
| RADX Radiopharm Theranostics Limited | C- | 61/100 | — | — | — | +17.52% | $16.1M | /radx-vs-neup → |
| JAGX Jaguar Health Inc. | E | 31/100 | — | 67.2% | -35.0% | -2.86% | $15.9M | /jagx-vs-neup → |
| AEON AEON Biopharma Inc. (Class A) | D | 48/100 | — | — | -35.0% | +11.36% | $17.4M | /aeon-vs-neup → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-06-30 • CIK 0001191070In its most recent audited fiscal period (FY2025, filed 2025-06-30), Neuphoria Therapeutics Inc. (NEUP) reported GAAP revenue of $15.6M (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$369.6K, operating cash flow of $77.2K, and free cash flow of $77.2K (+100.5% YoY). On the balance sheet, NEUP closed FY2025 with $36.6M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 5/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-06-30 | $15.6M | -$369.6K | $77.2K | $77.2K | $36.6M | — |
| FY2024 (FY) | 2024-06-30 | $0 | -$15.5M | -$14.7M | -$14.7M | $18.2M | — |
| FY2023 (FY) | 2023-06-30 | $0 | -$21.4M | -$14.6M | -$14.6M | — | — |
3. NEUP Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs NEUP stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, Neuphoria Therapeutics Inc. (NASDAQ: NEUP) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $3.06 (-8.93% 1D, market cap $16.6M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, NEUP ranks #899 in composite RQD confidence.
How does NEUP compare to MRKR and RADX in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), NEUP carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -11.8%. By comparison, MRKR (Marker Therapeutics Inc.) holds a D grade (48/100 RQD, P/E N/A, ROIC -35.0%, cap $16.8M) and RADX (Radiopharm Theranostics Limited) posts a C- grade (61/100 RQD, P/E N/A, ROIC —, cap $16.1M). Among the 5-stock peer group, NEUP leads on earnings multiple (N/A) while NEUP leads on capital efficiency (-11.8% ROIC).
What are the biggest fundamental strengths and SEC risk factors for NEUP?
Per NEUP's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-06-30, CIK 0001191070), Neuphoria Therapeutics Inc. generated $15.6M in revenue, -$369.6K in net income, and $77.2K in free cash flow against $36.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is NEUP trading relative to its 50-day, 200-day, and 52-week technical levels?
NEUP last traded at $3.06 (-8.93% on volume of 70,088 shares), positioning the stock -14.29% below its 50-day simple moving average ($3.57) and -26.44% below its 200-day simple moving average ($4.16). Across its 52-week range of $3.03 to $5.53, NEUP sits at the 1.2% percentile with a 14-day RSI of 25.4 (OVERSOLD (<32)) and an implied next-earnings move of ±7.7% ($2.82 to $3.30).
NEUP Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is NEUP stock moving today?
Why NEUP Stock dropped -8.93% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-12% return on capital) under elevated 10-year interest-rate pressure.